Preclinical study of CD19 detection methods post tafasitamab treatment

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Several CD19-targeted antibody therapies, including tafasitamab, are available for diffuse large B-cell lymphoma (DLBCL).
• Assessing CD19 expression after tafasitamab treatment is important for subsequent therapy sequencing.
• Standardized methods for CD19 detection in this context are lacking, risking misinterpretation due to epitope masking.

Purpose of the Study:

• To evaluate commercially available CD19 detection antibodies for immunohistochemistry (IHC) and flow cytometry (FC).
• To assess the impact of tafasitamab pre-treatment on CD19 detection.
• To identify optimal methods for accurate CD19 expression analysis in DLBCL patients treated with tafasitamab.

Main Methods:

• Analyzed commercial CD19 antibody clones using competition assays on tafasitamab-treated cell lines.
• Employed an acidic dissociation protocol to remove bound tafasitamab from cell surfaces.
• Measured antibody affinities using Surface Plasmon Resonance (SPR) and Bio-Layer Interferometry (BLI).

Main Results:

• All 7 tested IHC antibody clones detected CD19 on tafasitamab-treated samples.
• All 8 tested FC antibody clones competed with tafasitamab.
• Acidic dissociation was critical to overcome CD19 masking by tafasitamab and prevent false-negative FC results.

Conclusions:

• The choice of CD19 detection antibody and technique significantly impacts interpretation accuracy.
• Standardized methods are needed for reliable CD19 assessment in DLBCL patients undergoing tafasitamab therapy.
• These findings provide guidance for selecting appropriate tools and interpreting CD19 expression in clinical settings.